MetaCap

Aurinia Pharmaceuticals Inc (AUPH)

NASDAQ: AUPHHealth CareBiotechnology: Pharmaceutical PreparationsUSD

14.70-0.19 (-1.28%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

AUPH stock chart

Technical analysis

Key statistics

All statistics
52-week range
13.52 – 19.25
Day range
14.63 – 14.97
Volume / Avg
1.34M / 858.74K
Beta
—

52-week range

$13.52$19.25

AUPH stock today

Aurinia Pharmaceuticals (AUPH) closed at $14.70 on Nov 20, down 1.28% (-$0.19), versus the S&P 500's 3.70% decline. At this level, AUPH sits in the middle of its 52-week range of $13.52 to $19.25: 23.6% below the high, set on Jun 24, 2026 and 8.7% above the low. AUPH is down 7.8% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 6.3%.

Aurinia Pharmaceuticals trades at 6.4x its trailing twelve-month earnings per share of $2.28. Its forward P/E of 12.7x is higher than the trailing multiple, which means analysts expect earnings to decline over the next year.

Summary generated from market data by MetaCap's automated system. Methodology

About Aurinia Pharmaceuticals

Company profile

Aurinia Pharmaceuticals Inc., a biopharmaceutical company, engages in delivering therapies to people living with autoimmune diseases with high unmet medical needs in the United States and Japan. The company offers LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis. It also develops aritinercept, a dual inhibitor of B cell-activating factor and proliferation-inducing ligand for the potential treatment of autoimmune diseases.

Industry
Biotechnology: Pharmaceutical Preparations
CEO
Mr. Kevin C. Tang
Headquarters
Edmonton, AB
Employees
128

Financial highlights

Full financials

In fiscal 2025, Aurinia Pharmaceuticals generated $283.1 million in revenue, up 20.4% from fiscal 2024, its 4th consecutive year of revenue growth. Net income was $287.2 million (+4893.1% year over year), for a net margin of 101.5% versus a median of -80.7% in the prior 5 years. Gross margin was 88.5% (up from 88.0%) and operating margin 37.1%.

Aurinia Pharmaceuticals annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue$283.06M$235.13M$175.51M$134.03M$45.60M
Growth+20.38%+33.97%+30.95%+193.89%-9.00%
Net income$287.20M$5.75M$-78.02M$-108.18M$-180.97M
EPS (diluted)$2.07$0.04$-0.54$-0.76$-1.40

Analyst forecast

Forecast

Consensus (6 analysts)

buy

Avg. price target

$18.50+25.85%

  • Strong buy 0
  • Buy 4
  • Hold 2
  • Sell 0
  • Strong sell 0

Target range

Low $16.00High $21.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 3, 2026
EPS actual vs est.
$0.23 vs $0.20
Surprise
+15.00%

AUPH news

All AUPH news

Aurinia Pharmaceuticals peers

Health Care sector
AUPH peer companies
CompanyPrice% ChgMarket capCompare
HRMYHarmony Biosciences Holdings Inc.32.59-1.18%$1.91Bvs AUPH
TRVITrevi Therapeutics Inc.13.35-2.70%$1.90Bvs AUPH
PVLAPalvella Therapeutics Inc.142.85-2.00%$2.09Bvs AUPH
BHVNBiohaven Ltd.12.39-9.23%$1.87Bvs AUPH
IMNMImmunome Inc.15.69-5.54%$1.85Bvs AUPH
VERAVera Therapeutics Inc. Class A25.45-4.86%$1.84Bvs AUPH
SEPNSepterna Inc.38.61-1.51%$1.84Bvs AUPH
MRVIMaravai LifeSciences Holdings Inc. Class A6.98-2.92%$1.81Bvs AUPH

Indexes, lists and sector

Aurinia Pharmaceuticals stock FAQ

What is Aurinia Pharmaceuticals's stock price today?

AUPH last traded at $14.70 as of Nov 20, 4:00 PM EST, down 1.28% on the day. Prices are delayed at least 15 minutes.

What is AUPH's P/E ratio?

AUPH trades at a trailing P/E ratio of 6.45 and a forward P/E of 12.67.

Who is Aurinia Pharmaceuticals's CEO?

Mr. Kevin C. Tang is the chief executive officer of Aurinia Pharmaceuticals Inc, which has about 128 employees.

What is the AUPH 52-week high?

The 52-week high for AUPH is $19.25 and the 52-week low is $13.52. The stock is currently 23.6% below its high.

Compare AUPH